Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1980 Apr;34(1):130–135. doi: 10.1128/jvi.34.1.130-135.1980

In vitro cytotoxicity against Marek's disease lymphoblastoid cell lines after enzymatic removal of Marek's disease tumor-associated surface antigen.

K A Schat, K K Murthy
PMCID: PMC288678  PMID: 6966335

Abstract

Marek's disease tumor-associated surface antigen (MATSA) has been claimed to be the target of cytotoxic lymphocytes in in vitro tests for Marek's disease immunity. Treatment with papain, but not with trypsin or mixed glycosidases, removed MATSA from certain Marek's disease lymphoblastoid cell lines. Tumor cells with and without MATSA were used as target cells for in vitro studies on cell-mediated immune responses with sensitized spleen cells in a chromium release assay. The removal of MATSA did not influence the results of the chromium release assay. Attempts to block the cell-mediated cytotoxicity in vitro by coating tumor cells with an anti-MATSA serum failed. It was concluded that cell-mediated immune responses against Marek's disease tumor cells are directed against an as yet undefined antigen(s).

Full text

PDF
130

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama Y., Kato S. Two cell lines from lymphomas of Marek's disease. Biken J. 1974 Sep;17(3):105–116. [PubMed] [Google Scholar]
  2. Calnek B. W., Carlisle J. C., Fabricant J., Murthy K. K., Schat K. A. Comparative pathogenesis studies with oncogenic and nononcogenic Marek's disease viruses and turkey herpesvirus. Am J Vet Res. 1979 Apr;40(4):541–548. [PubMed] [Google Scholar]
  3. Calnek B. W., Murthy K. K., Schat K. A. Establishment of Marek's disease lymphoblastoid cell lines from transplantable versus primary lymphomas. Int J Cancer. 1978 Jan 15;21(1):100–107. doi: 10.1002/ijc.2910210117. [DOI] [PubMed] [Google Scholar]
  4. Hahn E. C., Ramos L., Kenyon A. J. Lymphoproliferative diseases of fowl: JM-V leukemic lymphoblasts in cell culture. J Natl Cancer Inst. 1977 Jul;59(1):267–271. doi: 10.1093/jnci/59.1.267. [DOI] [PubMed] [Google Scholar]
  5. Higgins D. A., Calnek B. W. Fowl Immunoglobulins: Quantitation in Birds Genetically Resistant and Susceptible to Marek's Disease. Infect Immun. 1975 Aug;12(2):360–363. doi: 10.1128/iai.12.2.360-363.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Murthy K. K., Calnek B. W. Pathogenesis of Marek's disease: early appearance of Marek's disease tumor-associated surface antigen in infected chickens. J Natl Cancer Inst. 1978 Sep;61(3):849–854. [PubMed] [Google Scholar]
  7. Murthy K. K., Dietert R. R., Calnek B. W. Demonstration of chicken fetal antigen (CFA) on normal splenic lymphocytes, Marek's disease lymphoblastoid cell lines and other neoplasms. Int J Cancer. 1979 Sep 15;24(3):349–354. doi: 10.1002/ijc.2910240313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Pearson G. R., Qualtiere L. F. Papain solubilization of the Epstein-Barr virus-induced membrane antigen. J Virol. 1978 Oct;28(1):344–351. doi: 10.1128/jvi.28.1.344-351.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Qaultiere L. F., Pearson G. R. Solubilization and characterization of Herpesvirus saimiri-induced membrane antigens. J Virol. 1978 Mar;25(3):852–859. doi: 10.1128/jvi.25.3.852-859.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ross L. J. Antiviral T cell-mediated immunity in Marek's disease. Nature. 1977 Aug 18;268(5621):644–646. doi: 10.1038/268644a0. [DOI] [PubMed] [Google Scholar]
  11. Schat K. A., Calnek B. W. Characterization of an apparently nononcogenic Marek's disease virus. J Natl Cancer Inst. 1978 May;60(5):1075–1082. doi: 10.1093/jnci/60.5.1075. [DOI] [PubMed] [Google Scholar]
  12. Schat K. A., Calnek B. W. Protection against Marek's disease-derived tumor transplants by the nononcogenic SB-1 strain of Marek's disease virus. Infect Immun. 1978 Oct;22(1):225–232. doi: 10.1128/iai.22.1.225-232.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sharma J. M. Cell-mediated immunity to tumor antigen in Marek's disease: susceptibility of effector cells to antithymocyte serum and enhancement of cytotoxic activity by Vibrio cholerae neuraminidase. Infect Immun. 1977 Oct;18(1):46–51. doi: 10.1128/iai.18.1.46-51.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sharma J. M., Coulson B. D. Cell-mediated cytotoxic response to cells bearing Marek's disease tumor-associated surface antigen in chickens infected with Marek's disease virus. J Natl Cancer Inst. 1977 Jun;58(6):1647–1651. doi: 10.1093/jnci/58.6.1647. [DOI] [PubMed] [Google Scholar]
  15. Sharma J. M. Role of tumor antigen in vaccine protection in Marek's disease. Adv Exp Med Biol. 1977;88:345–353. doi: 10.1007/978-1-4613-4169-7_32. [DOI] [PubMed] [Google Scholar]
  16. Sharma J. M., Witter R. L., Coulson B. D. Development of cell-mediated immunity to Marek's disease tumor cells in chickens inoculated with Marek's disease vaccines. J Natl Cancer Inst. 1978 Nov;61(5):1273–1280. doi: 10.1093/jnci/61.5.1273. [DOI] [PubMed] [Google Scholar]
  17. Svedmyr E., Jondal M. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1622–1626. doi: 10.1073/pnas.72.4.1622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Witter R. L., Stephens E. A., Sharma J. M., Nazerian K. Demonstration of a tumor-associated surface antigen in Marek's disease. J Immunol. 1975 Jul;115(1):177–183. [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES